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Abstract.  To understand the secretion and processing 
of interleukin-1  (IL-1), a Chinese hamster fibroblast 
cell line (R1610) was transfected with a  human IL-113 
cDNA under the control of the SV40 early promoter 
and linked to the gene for neomycin resistance.  After 
selecting for transfected cells resistant to G418,  two 
clones were found to constitutively express the IL-113 
31-kD precursor which was almost exclusively located 
in the cytosol. Pulse-chase experiments failed to show 
any secretion of IL-1 and very little IL-1 activity was 
detectable in cell supernatants.  Furthermore, surface 
membrane IL-1  activity could not be detected, al- 
though low levels of activity could be released upon 
brief trypsin treatment.  Therefore, unlike monocytes, 
these fibroblast cells lack the mechanism for secreting 
and processing of IL-113. 
I 
NTERLEUKIN-I (IL-1) j is the collective name given to a 
group of polypeptide hormones that share a number of 
properties, including the activation of T cells, stimula- 
tion of B cell differentiation, stimulation of acute phase pro- 
tein synthesis in hepatocytes, stimulation of prostaglandin 
and protease synthesis in synovial and chondrocyte cells, and 
augmentation of fibroblast proliferation (10, 38).  Further- 
more these molecules are endogenous pyrogens. Since the 
production of IL-ls is stimulated by infection and injury, it 
is likely that they mediate many of the important responses 
to insults and inflammation. 
Recently,  two  genes  have  been  isolated  from  humans 
which encode the two major isoelectric forms of IL-1 (3, 8, 
12,  13,  16,  28,  31). These have been designated ct for the 
pI 5 form and 15 for the pI 7 form (31). Both proteins are en- 
coded as 31-kD precursors which are subsequently processed 
and secreted as a  mature,  active  17-kD carboxyi terminal 
fragment. However, the full sequence of the 31-kD precursor 
does not appear to contain the standard hydrophobic signal 
sequence known to direct the secretion of most exported eu- 
karyotic proteins studied to date (20). It is therefore of in- 
terest to understand how this apparently unique class of mol- 
ecules is secreted from cells. 
In many cell types the induction of IL- 1, as monitored by 
the appearance of its activity in the supernatant, requires ex- 
ternal  stimuli  such as  PMA or lipopolysaccharide (LPS). 
This  is  particularly true of monocytes and monocyte cell 
lines, which appear to be the predominant source of IL-1 
(22, 38). In addition to inducing IL-1 mRNA, these agents 
I.  Abbreviations  used in  this paper:  BPV,  bovine papilloma virus; galk, 
galactokinase;  IL-I,  lnterleukin  1;  LPS,  lipopolysaccharide;  tPA,  tissue 
plasminogen activator. 
cause substantial changes in morphology and reduce the via- 
bility of the cells. This has led to speculation that IL-1 may 
not be actively secreted, but may be passively released by 
damaged cells (14,  17). One way of addressing this question 
directly is to ablate the toxic effects of external stimuli by ex- 
pressing the IL-1 precursor constitutively in a fibroblast cell. 
Stimulus induced cell damage should be kept to a minimum 
and we can examine the ability of the IL-1  to be secreted 
from viable cells. 
In this study, we have transfected a vector encoding the full 
length 31-kD precursor under the transcriptional control of 
the SV40 promoter into rodent fibroblasts, and have obtained 
cloned cells which constitutively express high levels of IL-113 
precursor.  These  cells  lines  have  allowed  us  to  assess 
whether  the  IL-1  precursor  protein  encodes  the  signals 
necessary for secretion. Furthermore, there have been a few 
reports suggesting that IL-1 activity can be found associated 
with the plasma membrane of cells expressing IL-1  (24), 
which has led to models supporting an independent role for 
this bound form of IL-1 in T cell activation (25). We have 
therefore examined these same cell lines for their ability to 
express membrane IL-1. 
Materials and Methods 
Plasmid Construction 
Cloning of the human I1-113 cDNA and expression of fully active, mature 
17-kd IL-II3 from it has been described previously (36). The precursor cod- 
ing region was isolated from the cDNA by cutting first with Acc I, filling 
in the overhang with Klenow, followed by partial digestion with Nco I. The 
partially digested 900 bp Nco l/Acc I restriction fragment was then purified 
by agarose gel electrophoresis, electroelution, and desalting via a prepack- 
aged  NACS  column  (Bethesda  Research  Laboratories,  Bethesda,  MD). 
This fragment was then ligaled to the plasmid vector DSP1 (40) which had 
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lowed by phosphatase. The plasmid obtained, DSPIL-I13, placed the IL-113 
precursor coding sequence under the control of the SV40 early promoter 
and RNA start and polyadenylation sites, with the Nco I  site religation 
reconstituting the strong Kozak consensus sequence for initiation of protein 
translation (21). 
This transcription cassette was then transferred into a mammalian clon- 
ing vector bovine papilloma virus (BPV)-13 globin-neo, which consists of 
the complete BPV genome, the ampicillin resistance gene of pBR322 for 
selection in bacteria, and the neomycin resistance gene under the control 
of the human 13-globin promoter and SV40 early polyadenylation regions 
for selection in mammalian cells via resistance to G418 (Reff, M., personal 
communication).  This was achieved by digesting DSPIL-113 with Sal  I, 
purifying the 1.5-kb fragment containing the IL-113 transcriptional cassette 
via electrophoresis as above, and ligating to BPV-13-globin-neo which had 
been previously cut with Sal I and phosphatased. The plasmid obtained was 
called BPV-IL-113 (see Fig. 1). As controls we used two vectors: BPV galac- 
tokinase (BPV-galk) and BPV-tPA which constitutively express the bacterial 
galk and human tissue plasminogen activator (LPA) genes respectively in 
BPV constructs similar to BPV-IL-113 (Reff, M., personal communication). 
Plasmids used for cloning or transfections were purified via the alkaline 
lysis method (7), followed by digestion with boiled RNAse A and chroma- 
tography through Bio-Gel A-150 (Bio-Rad Laboratories, Richmond, CA) 
(30)  with minor modifications from the published procedures. Restriction 
enzymes, Calf intestinal phosphatase, DNA polymerase, Klenow, and T4 
DNA ligase were obtained from New England Biolabs,  (Beverly,  MA), 
Bethesda Research Laboratories or Boehringer-Mannheim (Houston, TX) 
Deoxyribonuclease I was obtained from Cooper Biomedical (Malvern, PA). 
Cell Culture, Transfection, and Cloning 
Chinese hamster R1610 cells (galk-, hgprt-) (47) were maintained in DME 
supplemented with 10% fetal bovine serum, 20 mM L-glutamine, and peni- 
cillin/streptomycin (all from Gibeo, Grand Island, NY).  10 I.tg BPVIL-113 
DNA  was  transfected  into  1  x  106  cells  via  the  calcium  phosphate 
coprecipitation technique (50). After 16 h, the cells were split 1:3 and grown 
in the presence of 400 ~tg/ml of active commercial G418 (Gibeo). After sev- 
eral days of selection, the parent cells were completely killed and resistant 
colonies were large enough to be harvested with cloning cylinders. Two 
clones, 5.1  and 6.1, which were found to constitutively synthesize IL-113 
precursor were henceforward grown under identical conditions to the parent 
cell line, but were maintained in 400 I.tg/ml active G418. All cell lines used 
were found to be mycoplasma free. 
Activated human peripheral blood monocytes were prepared from Red 
Cross buffy coats by centrifugation through Ficoll and Pereoll gradients (9), 
followed by adherence to plastic tissue culture dishes for 1.5 h  in RPMI 
medium (Gibco) containing 1% human AB serum (Irvine Scientific, Santa 
Ana, CA). All media and reagents used contained less than 0.03 ng endo- 
toxin as determined by Limulus Amoebocyte Lysate (Associates from Cape 
COd,  MA).  The attached monocytes were then activated with  10 ng/ml 
Escherichia coli LPS in 1% human AB serum and RPMI. RNA and protein 
were prepared from these cells as described below. 
Southern Blots 
Genomic DNA  was prepared from R1610 cells and G418  resistant cell 
clones by resuspending ix,107 ceils in 2 ml NTE buffer (0.1 M NaCI, 0.01 
M Tris-HC1,  pH 8.0, 1 mM EDTA), and then adjusting the suspension to 
20 mM EDTA, 0.2%  SDS and mixing. After incubation with 100 p,g/ml 
boiled RNAse A (Sigma Chemical Co., St. Louis, MO) at 37°C for 2 h, 
followed by 100 I.tg/ml proteinase K for 2 h at 37°C, the solution was gently 
extracted a few times with phenol/chloroform and dialysed against NTE. 
Concentration and  purity  was then assessed by  absorbance at  260  and 
280 nm. 
After restriction endonuclease digestion using the manufacturers recom- 
mended conditions, the DNA was fractionated on 0.7 or 1% agarose gels 
and transferred to 0.45  ~m nitrocellulose (Schliecher &  Schuell, Keene, 
NH) according to standard methods (30, 43). Prehybridization and hybrid- 
ization of the blots were by the method of  Wahl et al. (49). Blots were probed 
with a nick-translated human IL-113 cDNA fragment (36) labeled to •3  x 
108 cpm/I.tg with [ct32p] dNTPs (>3,000CJmmol, Amersham Corp.) (30). 
For direct comparison of mobility, purified BPVIL-I13  plasmid DNA was 
digested with the same enzyme as the genomic sample to be quantitated, 
and an appropriate dilution run with digested control R1610 DNA. 
Northern Blots 
RNA was prepared by the guanidinium thiocyanate-cesium chloride cushion 
method (30, 35). Poly A+ mRNA from activated monocytes was obtained 
by oligo-dT chromatography (Collaborative Research) (4). RNA was frac- 
tionated on 1.5 % formaldehyde-agarose  gels (30) and transferred to 0.45 I.tm 
nitrocellulose (Schliecher &  Schuell) by established methods (48).  Pre- 
hybridization and hybridization with nick translated probes was performed 
as outlined above for Southern blots. 
Westerns 
A  rabbit anti-rIL-113  polyclonal antiserum was generated by injecting rab- 
bits with Escherichia coli produced 17-kD recombinant IL-I13 (19). Protein 
samples that had been previously boiled in SDS-loading buffer (26)  were 
run on a  15%  SDS-polyacrylamide gel (26).  For tPA, samples were first 
boiled in SDS and then denatured in 6 M  Urea before electrophoresis on 
10% SDS-PAGE in a continuous buffer system to eliminate aggregation of 
glycosylated protein.  Proteins were subsequently transferred to 0.22  ~tm 
nitrocellulose (Schliecher &  Schuell) via electroblotting (Bio-Rad).  The 
nitrocellulose was then dried,  rehydrated in  1  x  PBS  (0.137 M  NaCI, 
2.7 ram KCI,  1.3 mM KH2PO4, 9.5  mM Na2HPO4),  and then incubated 
with a 2 % solution of nonfat dried milk (Carnation) in 1 x  PBS at 4°C for 
1 h.  A  1:2,000 dilution of rabbit anti-rIL-113  or rabbit anti-tPA antiserum 
was then added in 0.5% nonfat milk/l  x  PBS and the incubation continued 
for 16 h at 4°C. The filter was washed 2-3 times with 1  x  PBS at room 
temperature for 20 min each and then incubated with a  1:10,000 dilution of 
~251-1abeled protein A (0.16 mCi/ml; ICN) in 0.5% non-fat dried milk and 
1 x  PBS at room temperature for 1 h followed by four 15-min washes with 
1  x  PBS at room temperature, before autoradiography. 
3~S labeling of Precursor and Mature rlL-l[3 
The genes encoding both the precursor and mature forms of IL-113 were 
cloned into an inducible E. coli expression vector under control of the k PL 
promoter (36, our unpublished studies). Overnight cultures grown at 32°C 
in modified M56 minimal medium with biotin and ampicillin (50 Ixg/ml) 
were diluted 1:10 in fresh medium and grown to an A60o of 0.6, at which 
time the temperature was raised to 42°C by the addition of V2 volume 65°C 
medium.  Cells  were incubated for  1 h  at  42°C,  then centrifuged, and 
resuspended in an equal volume of unmodified M56 supplemented with 
0.2 % glucose, 1 v.g/ml thiamine, 2 I.tM amino acids minus cysteine and me- 
thionine, biotin, ampicillin, and 20  p.Ci of Trans35S-label  (85%  methio- 
nine,  15%  cysteine, ICN,  >1,000  Ci/mmol).  The cells were labeled for 
20 min at 42°C, centrifuged and the pellets frozen on dry ice. 
Before use, the pellets were resuspended in one-fifth volume of lysis 
buffer (40 mM NaCI, 50 mM Tris-HC1, pH 8.0, 1 mM EDTA, 1 mM DTT) 
plus 2 mM PMSF and sonicated for 30 s using a Branson Sonifier.  Sonicates 
were centrifuged in  an  Eppendorf microfuge for 30  min.  For  stability 
studies, 10 I11 of supernatant was then added to dishes containing 1 x  106 
6.1 cells and 2.5 ml 1% fetal bovine serum (Gibco) in DME, and incubated 
for various times before immunoprecipitation as described below. 
Immunoprecipitation 
Stable R1610 transfected cells containing BPVIL-11~, BPV tPA or BPVgalk 
were labeled by seeding 1  x  106 cells in a  100 mm dish, and  16 h later 
washing three times with 1 x  PBS before incubating with 5 ml methionine 
and cysteine free MEM (Gibco) and 1% dialyzed fetal bovine serum (Gibco) 
for 1 h. After 3 more washes with 1  x  PBS, the cells were then labeled 
for 5 h with 150 ~CJml [35S]methionine (>800Cdmmol, Amersham Corp.) 
and  165  ltCi/ml  [35S]cysteine (>600Ci/mmol,  Amersham Corp.)  in  the 
above serum and medium. The supernatants were harvested, and the cells 
washed 3x with 1 x  PBS and either lysed immediately in 0.5 ml 1 x  RIPA 
(0.15  M  NaCI,  10 mM Tris-HC1,  pH 7.5,  1%  deoxycholate,  1%  Triton 
X-100, 0.1% SDS, 10 mM EDTA, 2 mM PMSF) or incubated for a further 
20 h with 2 ml fresh MEM (Gibco) containing 1% fetal bovine serum before 
harvesting as above. 
Cell lysates were made 2% milk by adding an equal volume of 4% nonfat 
dry milk in 1 x  RIPA. Protein A-Sepharose beads (50 ~1 half-packed vol- 
ume) (Bio-Rad) were added to 0.5 ml of this solution and then incubated 
at 4°C for 1 h on a rotator.  After centrifugation at 10,000 rpm for 10 min 
in a  Beckman model TJ6  tabletop centrifuge, the supernatants were in- 
cubated with  1:200 anti-rlL-113  polyclonal antisera (see above) or  1:200 
anti-tPA for 1-16 h at 4°C, followed by a further 1 h incubation in the pres- 
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described previously, washed twice in 2 ml RIPA buffer,  10 rain each, and 
one time in I ml of low salt buffer (20 mM Tris-HCI, pH 7.4, 25 mM NaCI). 
After the final wash, beads were resuspended in 45 gl of SDS loading buffer 
and boiled for 5 min. Beads were removed by centrifugation, and one third 
of supernatant was subjected to electrophoresis on a  15% SDS-polyacryl- 
amide gel (26). Gels were fixed for 1 h in 5% methanol, 10% glacial acetic 
acid, soaked for 20 min in Amplify (Amersham Corp.) and then vacuum 
dried before autoradiography. 
Media fractions were made 0.5 or 2%  milk for tPA or IL-I detection 
respectively by the addition of  an equal volume of I or 4% milk in 1 × RIPA 
buffer.  100 gl protein A-Sepharose beads were used and the beads were 
washed twice with 4 ml  1  x  RIPA. 
Monocytes prepared as described above, were activated with 10 ng/ml 
LPS for 2 h in methionine-free MEM and 5% fetal bovine serum (Gibeo), 
washed with 1 ×  PBS, and incubated for a further ! h in the same medium 
with 100 I.tCi/ml [35S]methionine.  The cells were then washed twice with 
!  ×  PBS, and either harvested in 1 x  RIPA or incubated in 5% fetal bovine 
serum and RPMI for a  further 24 h.  The supernatant was removed and 
diluted with an equal volume of 2 x  RIPA. Both supernatant and cell lysate 
were first incubated with 50 gl rabbit preimmune serum for 1 h followed 
by 50 gl Immuno-Precipitin (formalin-fixed Staph A, BRL)  for an addi- 
tional hour with rotation. The Staph A were then pelleted by centrifugation 
at 3,000 rpm for 5 min and the supernatant fractions incubated with 1:100 
dilution of rabbit anti-IL-1 [3 for 1 h, followed by 50 I.tl Immuno-precipitin 
for 1 h with rotation. The samples were then centrifuged at 3,000 rpm for 
5 min, and washed four times with 1  ×  RIPA before resuspension in gel 
loading buffer and analysis via SDS-PAGE (26). 
Immunofluorescence 
Cells were seeded at ",,5  ×  105 cells/well in 4-well chamber slides (Fal- 
con). After washing the slides twice with PBS, cells were fixed by incuba- 
tion in ice cold ethanol for 10 rain. Slides were then air dried and the cells 
blocked by incubation for 1 h at 37°C with nonconjugated goat anti-rabbit 
IgG (Cappel) diluted 1:250 in 1 ×  PBS. The cells were washed twice with 
1 ×  PBS and then incubated with polyclonal anti-rlL-l~ antisera diluted 
1:200 in 1 ×  PBS. After 1 h at 37°C, slides were washed as before and then 
incubated with FITC-labeled goat anti-rabbit IgG (Cappel) diluted 1:1,000 
for 1 h at 37°C.  The ceils were washed as above and the slides mounted in 
glycerol. Slides were examined using phase contrast and fluorescence mi- 
croscopy (Zeiss Universal). 
Fractionation and Harvesting of  Cellular 
Associated IL-1 
Approximately 1  ×  107 cells were fractionated using the method of Mat- 
sushima et al. (34) resulting in three fractions: cytosolic, membrane, and 
particulate, the last representing cellular organelles. The purity of each frac- 
tion was assessed via assays for cytosol (lactate dehydrogenase) and mem- 
brane (5' nucleotidase) specific enzymes (5). Lactate dehydrogenase activity 
was assayed by determining the decrease in A340 resulting from the oxida- 
tion of NADH (Worthington Catalogue, 1982).  5'-Nucleotidase activity was 
determined with a Sigma Chemical Co. diagnostic kit (procedure No. 675). 
Greater than 70% of the total lactate dehydrogenase activity remained as- 
sociated with the cytosolic fraction. In contrast, less than 20% of the total 
5' nucleotidase activity localized to the cytosol, indicating that the cytosol 
was only slightly contaminated by membrane components. Quantitation of 
relative amounts of IL- 113 precursor and tPA in each fraction was by densito- 
metric analysis of a Western blot. 
To harvest for cell associated IL-1 activity,  cells were scraped off tissue 
culture dishes with a rubber policeman in  1 x  PBS, centrifuged at  1,500 
rpm in a bench top centrifuge, and washed a second time in 1 x  PBS before 
freezing in dry ice and storage at  -70°C. The cells were then thawed in 
RPMI medium, sonicated, the debris removed by centrifugation, and the 
supernatants  assayed  as  below.  Alternatively,  the  pelleted  cells  were 
resuspended in 0.5  ml 50 mM octaglucopyranoside (octyl I~-o-glucoside, 
Sigma Chemical Co.), and allowed to lyse on ice for 5 min. The lysate was 
then dialysed 3 times with 1 1 RPMI medium (Gibco) at 4°C over a  16 h 
period. The precipitate that formed was then removed by centrifugation at 
10,000 rpm in a Beckman JA13 for 10 min, before assaying for activity. 
The protocol for releasing IL-I activity from 6.1 and R1610 cells was as 
follows. 60-ram dishes each containing 106 cells were washed twice with 
1 x  PBS, and then 1 ml 0.04% trypsin in 0.5 mM EDTA was added and 
distributed over all the attached cells. Within 20 s, most of this solution was 
suctioned off, leaving ,x,0.1 ml. After incubation with the cells for various 
time periods, 0.5 ml 0.25 % soybean trypsin inhibitor (Sigma Chemical Co.) 
in RPMI medium was added to the plate, and distributed evenly. The cells 
were then lifted from the plate via pipetting, and the solution centrifuged 
at 1,500 rpm in a Beckman TJ-6 centrifuge to remove cells. The supernatant 
was then assayed for IL-1 activity.  The cells were resuspended in 1 x  PBS 
and checked for viability by trypan blue staining. Viability was more than 
99%  out to 4  min of trypsin digestion. 
Assay  for IL-1 Activity 
IL-1 activity was determined by the EL-4 thymoma assay (42) in which the 
IL-2 production induced in EL-4 cells costimulated with calcium ionophore 
A23187  is assayed by measuring [3H]thymidine  incorporation in the IL-2 
dependent CTL20 cell line. To assay putative surface membrane IL-1 activ- 
ity, duplicate transfected and control R1610 cells were seeded in two-fold 
dilutions into a 96-well microtiter dish starting with 1-2  x  10  ~ cells. After 
overnight incubation in  10%  fetal bovine serum and DME lacking G418, 
the supernatants were harvested and tested directly in the EL-4 assay. Mean- 
while, the R1610 cells were washed several times with 1 ×  RPMI before 
adding 1 x  106 EL-4 cells to each well in assay medium, and incubating 
overnight at 37°C. The supernatants from these coincubations were then in- 
cubated with CTL20 cells in the usual manner. 
Results 
Construction of Vector  for IL-1 Expression 
To  attain  high  level  constitutive  expression  of the  31-kD 
IL-113 precursor, we placed the IL-11~ cDNA under the con- 
trol  of the  SV40  early  promoter  and  polyadenylation  se- 
quences,  by constructing  the  plasmid  DSPIL-113  (Fig.  1, 
top). The complete transcription unit was then inserted into 
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Figure 1.  Eukaryotic expression for human IL-11~. (Top) DSPIL-113; 
(bottom)  BPVIL-113.  Only key  restriction sites are included.  See 
Materials and Methods for detailed description of these plasmids. 
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DNA from R1610 cell lines was digested with the indicated restric- 
tion  enzymes,  separated  on a 0.7% agarose gel,  transferred to 
nitrocellulose, and hybridized to a  human IL-113 cDNA probe. 
(Lane/) R1610 cells mixed with 5 ng BPVIL-II3 DNA cut with 
Kpn I; (lanes 2 and 6) R1610 cells; (lane 3) RI610 cells transfected 
with BPVgalk; (lanes 4, 7-10, and 11) 6.1 cells; (lane 5) 5.1 cells. 
The arrow marks the migration of the linearized BPVIL-113  vector. 
a BPV vector, which contains the complete BPV genome, 
and the genes for neomycin and ampicillin resistance for se- 
lection in mammalian and bacterial cells respectively. This 
final plasmid was named BPVIL-11~ (Fig.  1, bottom). 
Transfection and Cloning of CeUs Constitutively 
Expressing IL-113 Precursor 
We  selected  for transfection a  Chinese  hamster  cell  line 
R1610,  which  had  been  previously  used  for  its  galk- 
background (47), but was particularly convenient because of 
its very short cell cycle. Hence, the time required for trans- 
fection and cloning in  selective media could be kept to a 
minimum.  BPVIL-11~ was transfected into R1610 cells via 
calcium phosphate precipitation (50), and after selection for 
several days in G418, 20 resistant clones were picked. To fur- 
ther screen amongst these clones for those expressing IL-113, 
we  initially  tested  the  supernatants  from  these  resistant 
clones for IL-1 activity using the EL-4 thymoma assay.  All 
20 clones were negative. 
Since it was possible that the cells could synthesize but not 
secrete the IL-1, we screened cell lysates via Western blot 
using  rabbit  polyclonal  antisera  specific  for  IL-11~. Two 
clones, 5.1 and 6.1, were identified which expressed the 31 
kD  IL-113 precursor  (see below),  and  these  were studied 
further. 
Characterization  of Transfected D NA 
We determined the status of the transfected IL-1 sequences 
in 5.1, 6.1  and control R1610 genomic DNAs via Southern 
blot (Fig. 2). Digestion of 5.1 and 6.1 DNA with Kpn I (lanes 
4 and 5), which cuts just once within BPVIL-1I~, yielded a 
13.7-kb linear IL- 113 fragment which comigrated with the lin- 
earized vector (lane 1) and was absent in DNA from untrans- 
fected R1610 cells and R1610 cells transfected with a control 
vector BPVgalk, which expresses the E. coli galactokinase 
gene (lanes 2 and 3). This indicates that the complete vector 
sequences have been retained intact in 5.1  and 6.1. 
Furthermore, the vector is integrated in multiple tandem 
repeats,  since  digestion  with enzymes which  cut once in 
BPVIL-  11~ (Kpn I, Pvu I, Mlu I, and Xmn I) revealed weakly 
hybridizing junction fragments in addition to the strongly 
hybridizing linearized vector sequences (lanes  7-10). Also 
digestion with Apa I, which does not cut BPVIL-113, results 
in a very large DNA fragment (>25 kb). If the vector had 
been episomal, we would have expected Apa I digestion to 
yield uncut supercoils, which should run further into the gel. 
Characterization  6f  lL-1 mRNA 
We checked for synthesis of IL-11~ mRNA in 5.1 and 6.1 by 
Northern blot. As shown in Fig.  3, both cell lines produce 
IL-113 mRNA with a size of "01.1 kb, which is absent in un- 
transfected R1610 cells. The size of the mRNA matches that 
predicted from the vector construct, and is smaller than the 
endogenous  IL-11~ mRNA  produced  in  activated  human 
monocytes (Fig. 3, lane 4) (31). We quantitated the level of 
IL-113 mRNA by comparison of  hybridization intensity in dot 
blots to a standard IL-113 mRNA synthesized in vitro from 
an SP6 vector by SP6 polymerase (23). (Smith, M., unpub- 
lished data).  This indicated that IL-113 constituted ,o1%  of 
the total RNA in both transfected cell lines. For comparison, 
IL-113 represents ,04-9 % of the mRNA in activated mono- 
cytes (Smith, M., and P.  Young,  unpublished data). 
Synthesis of  31-kD IL-1[3 Precursor 
When cell lysates  from 5.1  and  6.1  cells are analyzed by 
Western blot using rIL-l[~ specific antiserum (Fig. 4, lanes 
3 and 4), it can be seen that both synthesize high steady state 
intracellular levels of the predicted 31-kD precursor which 
is not detected in untransfected R1610 cells (Fig. 4, lane 5). 
This protein comigrates with the intracellular product of ac- 
tivated human monocytes (Fig. 4, lane 2) and precursor IL- 
113 synthesized in E. coli (Fig. 4, lanes 6-9) (Hazuda, D. J., 
R. L. Webb, P. L. Simon, and P. R. Young, manuscript sub- 
mitted for publication) suggesting that neither of the eukary- 
otic forms is glycosylated (IL-I[3 contains a potential N-gly- 
cosylation site at residue  123  [3, 31]). 
As  in activated monocytes, there is no evidence for the 
presence  in  cell  lysates of processed forms of the  IL-113 
precursor that  comigrate with  the  mature  17-kD  form of 
IL-113 secreted from activated monocytes. Comparison of the 
intensity of IL-113 precursor in the transfected cell lines and 
activated monocytes (Fig. 4, lanes 2-4) to known amounts 
of purified recombinant IL-1I~ precursor (Fig. 4, lanes 6-9) 
Figure 3. Northern analysis of cell line RNA. 
8 ltg of  total RNA from 5.1, 6.1, and R1610 con- 
trol cells (Control) are compared with  1 lag 
poly A+  mRNA from LPS activated periph- 
eral blood monocytes (act. mon.) The blot was 
hybridized  to  a  1.1  kh  Pst  1 human  IL-1{5 
cDNA insert. Exposure time for the monocyte 
sample (20 min) was ,,o20 times less than that 
for the cell lines (6 h). 
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IL-II].  After  15%  SDS-PAGE,  samples  were 
transferred to nitrocellulose and IL-113  detected by 
incubation with rabbit anti-human  17-kD IL-11~. 
(Lane  1)  Freshly  isolated human  purified blood 
monocytes;  (lane  2)  adherent  human  peripheral 
blood monocytes activated with 10 ng/ml LPS for 
20 h.  (Lanes 3-5) transfected and untransfected 
R1610 cell lines. (Lanes 6-9) Different amounts of 
purified IL-11~ precursor as shown; (lanes 10--13) 
different  amounts  of purified  mature  IL-11] as 
shown. 
allows  an  approximate quantitation  of intracellular  IL-I[I. 
Hence, we find that 5.1  and 6.1  make an average •4-8  pg 
IL-113 precursor/cell, compared with the '~1 pg/cell made by 
activated  monocytes.  These  amounts  are  reproducible  in 
different preparations to within a factor of 2, although they 
do not take account of variations within each cellular popu- 
lation. 
To examine whether the IL-1 is secreted from the trans- 
fected  fibroblasts,  6.1  cells  and  a  control  R1610  cell  line 
transfected with BPV-galk were pulse labeled for 5  h  with 
[35S]methionine  and  [35S]cysteine,  and  harvested  immedi- 
ately or incubated for a further 19 h in cold medium. IL-1I] 
products were then detected via immunoprecipitation with 
rabbit polyclonal antisera raised to 17 kD rlL-11~. As can be 
seen in Fig. 5 a, the 31 kD precursor IL-11~ can be detected 
intracellularly at 5 h in BPVIL-11] transfected cells but not 
in control BPVgalk transfected cells (lanes 1 and 2).  How- 
ever, neither the precursor or mature form of IL-  11] could be 
detected extracellularly either at 5 h (lane 6) or upon chasing 
all the labeled precursor from the cellular fraction (lanes 4 
and 8).  A  variety of other labeling conditions consistently 
failed to demonstrate any secretion of IL-11~. 
In contrast, when the intracellular IL-113 precursor was la- 
beled to a similar extent in activated human monocytes (Fig. 
5 b, lane 9), both precursor, mature and one other processed 
form of IL-11~ were observed in supernatants after a similar 
chase time (Fig. 5 b, lane 10). The presence of lower molecu- 
lar weight forms of IL- 113 in monocyte cell lysates (Fig. 5 b, 
lane 9) was not reproducible and appeared to reflect the de- 
gree of exposure of the IL-113 precursor to endogenous pro- 
teases during lysis.  Also,  when degradation was observed, 
as in the present experiment,  the lowest molecular weight 
form of IL-1 consistently migrated faster than mature IL-113 
(Fig. 5 b, lane 10), suggesting that the cleavage events occur- 
ring in these lysis conditions do not reflect those occurring 
upon secretion (See reference 19 for more complete details 
of the kinetics of IL-1 secretion). 
Our inability to detect secreted precursor or mature IL-113 
in R1610 supernatants was not due to either form being inher- 
ently unstable,  since incubation of [35S]methionine  labeled, 
E. coli synthesized precursor and mature IL-lfl in 6.1 super- 
natants showed only limited degradation of the 31  kD form 
(t,~ =  14 h) and no degradation of the mature 17 kD form 
over a  24 h  period (Fig.  6).  Also,  the R1610  cells are not 
blocked in the ability to secrete proteins since we can detect 
other labeled proteins in 6.1 supernatants upon pulse labeling 
cells  with  [35S]methionine  (Fig.  7  A).  Furthermore,  in 
R1610 cells stably transfected with a BPV vector containing 
the human tissue plasminogen activator eDNA (BPVtPA), a 
gene product with a standard amino terminal signal sequence 
(39), we can readily detect tPA in culture supernatants (Fig. 
7  B)  Hence,  R1610  fibroblasts are unlike activated mono- 
cytes in that they cannot secrete IL-11]. 
Cytoplasmic Localization of  lL-l~ 
Given the  failure  of the  transfected  fibroblasts to  secrete 
Figure 5.  Pulse  labeling  and  immunoprecipitation  of RI610 cell 
lines and activated human monocytes. (a) R1610 cell lines were la- 
beled with [35S]methionine and [35S]cysteine for 5 h and harvested 
(lanes 1, 2, 5 and 6) or chased in nonradioactive medium for a fur- 
ther 19 h (lanes 3, 4,  7and 8). Lanes 1, 3, 5 and 7 (-) Represent 
control RI610 cells, and lanes 2, 4, 6 and 8 (+) represent 6.1 cells. 
Cell and supernatant fractions are as marked.  (b) Peripheral blood 
monocytes activated with  10 ng/ml LPS. Cells were activated for 
2 h,  labeled with  [35S]methionine/cysteine for 1 h  (lane  9),  and 
chased for a further 24 h in nonradioactive medium (lane 10). The 
two lanes represent the cell lysate and supernatant fraction as indi- 
cated. All samples were immunoprecipitated with a rabbit anti-hu- 
man IL-  113 antiserum before 15 % SDS-PAGE and autoradiography. 
Lanes 5-8 are exposed longer than lanes 1-4 to meet the limits of 
detection. 
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Thus precursor IL-11~ remains in the cytosol and does not 
transfer into intracellular organelles, in contrast to what has 
been found for other secreted proteins, but consistent with 
its lack of a hydrophobic signal sequence. 
Figure 6. Stability of precursor and mature IL-II~ in 6.1 superna- 
rants. E. coli  expressing precursor and mature human IL-II] were 
pulse labeled with  [35S]methionine, lysed, and centrifuged.  The 
crude soluble fractions were then separately incubated for various 
times with 6.1 cells in standard culture conditions as shown and the 
amount of IL-I remaining determined by immunoprecipitation with 
IL-I[~ specific antiserum,  SDS-PAGE, and autoradiography. 
IL- 113, we examined its intracellular location. This was done 
in two ways. First, we examined the intracellular distribution 
of IL-113 in fixed, permeabilized 6.1  cells via indirect im- 
munofluorescence using  a  rabbit  polyclonal  antiserum  to 
rlL-113 followed by a fluorescein-conjugated goat anti-rabbit 
antibody.  As  shown in Fig.  8,  many 6.1  cells stained uni- 
formly throughout the cytoplasm, at higher intensity than 
control R1610 cells. Preincubation of the rabbit anti-IL-1 I~ 
antiserum with purified recombinant IL-11~ reduced staining 
of 6.1 cells to background levels, demonstrating that the in- 
creased immunofluorescence was specifically due to IL-113. 
The lack of staining of all 6.1 cells could result from a lack 
of clonality after just one round of cloning, but this has not 
been investigated further. 
Secondly, we performed a fractionation of cell lysates into 
cytosolic, membrane and particulate fractions in the pres- 
ence  of EDTA/EGTA,  which  should  remove  all  weakly 
bound membrane-associated proteins (34).  Equal amounts 
of each fraction on a  per cell basis were then analyzed by 
SDS-PAGE  followed by  immunoblotting  with  antisera  to 
rlL-11]  as above. Fractions were also characterized by en- 
zyme assay (see Materials and Methods). As shown in Fig. 
9 A, the 31-kD precursor is predominantly in the cytosol. 
In  contrast,  fractionation of BPVtPA  transfected R1610 
fibroblasts showed that the secreted tPA was found predomi- 
Figure 7.  Secretion  of other 
proteins  from  RI610 cells. 
Transfected (6.1 and  tPA) or 
untransfected RI610 cells were 
labeled  with  [35S]methionine 
and  [35S]cysteine and  super- 
natants harvested as in Fig. 5. 
(A) 10 Ixl of each supernatant 
were directly analyzed by 15% 
SDS-PAGE and autoradiogra- 
phy  without  immunoprecipi- 
tation.  (B) Supernatants were immunoprecipitated with anti-tPA 
antiserum before 10% SDS-PAGE and autoradiography. (Lane 3) 
BPVtPA-transfected  R1610  cell supernatants; (lane 4) control R1610 
cell supernatants. 
Activity of  Transfected Cells and Cell Supernatants 
Although the data indicated that IL-113 was not to be found 
in significant quantities in either the supernatant or mem- 
brane of transfected cells, the methods used above are not as 
sensitive as assays for IL-1 activity. We therefore tested both 
cell supernatants and homogenized cell lysates for activity in 
the EL-4 thymoma assay.  We failed to detect any significant 
activity in either 6.1 or R1610 cell lysates and supernatants, 
with the exception that sometimes low levels of activity (<2 
units/ml) could be found in supernatants of 5.1 or 6.1 freshly 
plated at high cell concentrations (e.g.  1  x  l06 cells/ml). 
Such activity was never found in control BPVgalk transfected 
or untransfected RI610 cells plated at similarly high density 
(data not shown).  In contrast, if 5.1 or 6.1  cells were har- 
vested by lysing in  50 mM octaglucopyranoside and then 
dialyzing out the detergent, we could detect significant levels 
of activity (Table I), suggesting that the IL-113 being synthe- 
sized from the transfected DNA can become active with suit- 
able treatment. 
Lack of  Surface IL-1 Activity in Transfected Cells 
It has been reported that activated monocytes express an ac- 
tive membrane form of IL-1 that can be detected on the sur- 
face of fixed cells and membranes, and is therefore believed 
to exist on the surface of live cells (24). One of the criticisms 
of using fixed cells is that they might continue to release in- 
tracellular material into the supernatant, which could be then 
mistaken for "membrane" activity. A better test for surface 
IL-1 activity would be an assay with live cells, in which the 
potential confusion due to secreted IL-1 has been eliminated, 
as is the case with the present BPVIL-11~ transfected R1610 
cell lines. 
To test for membrane IL-1 in our transfected cell lines, we 
looked for IL-2 induction via a direct cell to cell interaction 
between the transfected fibroblasts and the target EL-4 cells. 
Hence, we incubated EL-4 thymomas with dilutions of live 
5.1, 6.1, BPVgalk-transfected R1610 cells and untransfected 
R1610 cells. To allow for maximum viability, the transfected 
and control R1610 fibroblasts were plated one day before the 
assay,  and washed extensively before EL-4 thymomas were 
added. However, in several attempts we failed to detect activ- 
ity from any of the cells, whether synthesizing IL-1 precur- 
sor or not (data not shown). 
Recently, we and others have been able to show that the 
31-kD IL-113 precursor has no activity in the EL-4 or other 
T cell assays (37, Hazuda, D. J., R. L. Webb, P. L. Simon, 
and P. R. Young,  manuscript submitted for publication). It 
is therefore possible that IL-113  precursor could be expressed 
on the surface and would go undetected under the present as- 
say conditions. We were also intrigued with the finding that 
low levels of activity were seen only in the supernatants of 
transfected cells after splitting cells by treatment with trypsin 
and  replating at high density  in fresh medium.  This sug- 
gested to us that IL- 1 activity might be released from the sur- 
face of cells by trypsin, perhaps as a result of processing of 
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fibroblast  synthesized  IL-113. Cells fixed with 
ethanol  onto slides were blocked with noncon- 
jugated goat anti-rabbit IgG diluted  1:250 in 1 
x  PBS  before  incubation  with  a  polyclonal 
anti-rlL-113 antiserum (1:200). The cells were 
then stained with FITC-labeled goat anti-rab- 
bit IgG (1:1,000) and photographed using fluo- 
rescent  illumination.  (A)  Phase  contrast  of 
R1610 cells shown in B; indirect immunofluo- 
rescence of(B) R1610 cells,  (C) 6.1 cells,  (D) 
Same as C but using anti-human rlL-  113 serum 
pre-blocked with excess dL-ll]. 
the precursor.  A  similar observation has been reported  for 
a  human monocytic cell line (34). 
Both transfected and control R1610 fibroblasts were there- 
fore treated with trypsin and proteolysis was halted at various 
times after addition with soybean trypsin inhibitor. As shown 
in Fig.  10, activity is released in a time dependent manner. 
The transitory nature of the IL-1 release is presumably due 
to the instability  of the mature,  active form of IL-1 toward 
further trypsinization (unpublished studies).  In contrast, we 
failed to observe any loss of cell  viability  via trypan blue 
staining  within the time frame of the experiment. 
Discussion 
Most secretory proteins examined to date have been charac- 
terized  by the presence  of a  hydrophobic stretch  of amino 
acids known as a signal sequence, which directs the translo- 
cation of the protein across the membrane of the endoplas- 
mic reticulum during synthesis. The protein is subsequently 
ushered out of the cell via exocytosis. Although in the vast 
majority  of secreted proteins  the  signal  sequence  is at the 
amino terminus and is removed upon translocation, there are 
other  proteins  such  as  ovalbumin  in  which  the  signal  se- 
quence  is  internal,  and  is  not removed upon translocation 
(45).  Hydropathicity  profiles  of  both  IL-la  and  IL-11~ 
Figure 9.  Western  blot of fractionated  6.1  and control cells.  Cell 
fractions from 6.1 and BPVtPA-transfected  R1610 ceils were ana- 
lyzed via Western blot after SDS-PAGE using rabbit anti-human 
rlL-113 and rabbit anti-tPA antisera.  Cells and fractions are as indi- 
cated. (A) 6.1 fractions were analyzed on 15% SDS-PAGE; (B) tPA 
fractions (lanes  1-3) and tPA standard  (120 ng, lane 4) were ana- 
lyzed on 10% continuous SDS-PAGE after further denaturation in 
urea. Amounts of each fraction loaded were equivalent on a per cell 
basis. 
Table I. lntracellular 1L-1 Activity of  R1610 
Cell Transfectants 
Cell lysate  Activity 
U/IO  6 cells 
5.1  24.6 
6.1  36.0 
R1610  <1.0 
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Figure 10. Release of IL- 1 activity 
upon trypsin treatment of trans- 
letted RI610 cells.  Parallel P60 
dishes each containing 106 cells 
were incubated with 0.04% tryp- 
sin solution in 0.5 mM EDTA for 
the times indicated, and the reac- 
tion was stopped by adding excess 
0.25 % soybean trypsin inhibitor. 
Supernatants were then  assayed 
for IL-1 activity by the EL-4 as- 
say. (Solid line) 6.1 cells; (dashed 
line) RI610 cells. 
precursors suggest that both proteins apparently lack any re- 
gion, either amino terminal or internal, which has sufficient 
hydrophobicity and length to qualify as a signal sequence (3, 
16, 28). To study whether IL-1 can be secreted despite these 
apparent shortcomings, we have examined its expression in 
transfected Chinese hamster fibroblasts. 
Despite  high  level  expression  of the  IL-113 precursor 
within the transfected R1610 cells, it is not secreted either as 
a  precursor or the active mature  17-kD form. Instead the 
IL-113 is present almost exclusively in the cytosol of  the trans- 
fected cells, and cannot be detected in significant quantities 
in the membrane or organelle fractions. Furthermore, we 
know this is a characteristic of IL-113 and not the host R1610 
cells, since another secretory protein which does contain an 
amino terminal signal sequence, human tissue plasminogen 
activator (tPA), is secreted upon transfection into these cells. 
By way of comparison, activated human monocytes also 
accumulate unprocessed precursor IL-113 intracellularly as 
judged by Westerns and immunoprecipitates of total cell ly- 
sates (see Figs. 4  and 5),  and immunofluorescent staining 
data (6, Hazuda, D. J., and P. R. Young, unpublished data). 
Unlike the transfected fibroblasts, however, monocytes se- 
crete IL-113 in both the precursor and mature forms (2,  15, 
19, Fig. 6). It is therefore likely that hamster fibroblasts lack 
some cellular factor(s) or  state  of physiology that  allows 
secretion of release of the intracellular IL-113. 
We believe that the inability to secrete IL-113 may be true 
for other  fibroblast cells,  since  we  have also  transfected 
BALB/c 3T3 fibroblasts with BPVIL-113 and obtained cell 
clones  which constitutively synthesize intraceUular IL-113 
precursor and yet are also unable to secrete IL-1 activity in 
any significant quantities (unpublished data). This result also 
seems to pertain to other cell types, including T cells (46), 
epidermal cells (17, 18, 29, 41), and B cells (32, 33), which 
have been reported to express endogenous intracellular IL-1 
activity and yet fail to secrete it. In particular, it was noted 
by Hauser et al.  (17) that A431  epidermal carcinoma cells 
only released IL-1 activity into the supernatant as the cells 
became less viable, suggesting that 'secretion' might really be 
due to cell 'leakiness'.  This finding may also be true for cell 
types such as glial and glioma cells (11), astrocytes and as- 
trocytomas (11, Lee, J. C., P.  L. Simon, and P.  R. Young, 
manuscript submitted for publication), given that the cells 
are often cultured either for long periods or without serum, 
conditions which are likely to reduce cell viability. 
In all these arguments, it is worth thinking in quantitative 
terms about the levels of IL-1 produced. In the present case, 
we calculate that ,o4-8 pg of IL-113 precursor is being pro- 
duced per cell. However~ we know that purified recombinant 
mature IL-113 has a specific activity of "o5  x  10  s units/mg 
in the EL-4 assay (36),  which means that  105 transfected 
fibroblasts should contain 0.5 gg pre IL-113 or ,,o2.5  x  105 
U of activity. Despite this prediction, we detect no activity 
in sonicates of these fibroblasts, and only low levels of ac- 
tivity upon cell lysis with the  dialysable detergent,  octa- 
glucopyranoside. These data are consistent with the finding 
that  the  IL-113 precursor  is  inactive  (31, 37).  We  have 
confirmed that this is the case by expressing the 31 kd form 
oflL-113 in E.coli (Hazuda, D. J., R. L. Webb, P. L. Simon, 
and P. R. Young, manuscript submitted for publication). The 
low levels of activity detected after detergent extraction of  the 
transfected cell lines presumably reflects partial cleavage of 
the precursor by membrane and/or vesicle derived proteases. 
Indeed, we have noticed that if activated monocyte cell ly- 
sates are harvested in the absence of protease inhibitors, we 
can detect significant degradation of the precursor, which is 
otherwise undegraded if such inhibitors are present during 
the lysis (2,  19).  This leads us to believe that the detection 
of intracellular IL-I activity may be a function of both the 
lysis conditions and intracellular protease concentrations as 
well as the actual levels of IL-I molecules present. Also im- 
portant in this regard is the finding that the IL-lu precursor 
is active (37), in contrast to the observations with IL-113. 
Even though there is no a priori.reason to believe that ei- 
ther precursor or mature IL-1 should be membrane bound 
proteins given their lack of potential hydrophobic spanning 
regions, a few papers have recently found activity associated 
either with fixed, nonpermeabilized cells or with membrane 
fractions (24, 25, 34). We have therefore addressed the ques- 
tion  of whether  fibroblasts  which  are  constitutively syn- 
thesizing IL-113 are able to present it on the outer membrane 
in an active form. With intact viable transfected fibroblasts, 
we have been unable to detect cell surface IL-1 activity. 
We have also looked for the presence of inactive IL-113 on 
cell surfaces via immunofluorescence and surface iodination 
experiments without success (unpublished data).  Although 
this negative result is apparently contradicted by the experi- 
ments in which mature, active IL-1 is released from cells 
upon very brief treatment with trypsin, the latter could be 
explained in terms of the trypsinization of precursor IL-113 
in a few leaky or nonviable cells. Thus even though typically 
20-50 U IL-1 are released from 106 transfected R1610 cells, 
this  represents  only  100  pg  mature  IL-113, which  is  the 
equivalent of the IL-1 content of 25-50 nonviable cells or 
<10-2%  of the  population.  Since this  is beyond even the 
best viabilities one is likely to achieve, we are unlikely to 
ever be able to rule out this possibility. Given the comparable 
levels of IL-113 synthesis in activated human monocytes, we 
would be concerned that the same caveat would extend to 
those studies (34). Clearly, this phenomenon is going to be 
very difficult to answer definitively, given the extraordinarily 
high activity of the IL-1 molecule. Similar quantitative argu- 
ments may also apply to secretion of IL-I from many of the 
cell lines that have been studied, where even long incuba- 
tions often yield very little activity on a per cell basis. This 
would tend to further support the view that IL-1 is leaked 
rather than secreted from these cells. Clearly, a more quan- 
titative evaluation similar to that described here may help to 
resolve this issue. What does appear to be true however, is 
that monocytes are much more proficient at releasing IL-1 
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properties or an excessive 'leakiness' awaits further studies 
of secretion in these cells. 
The findings in this paper lend support to a two step model 
for the secretion of IL-1 from many nonmonocytic cell lines. 
First, IL-1  is synthesized as a cytosolic protein in response 
to some external stimulus. Second, IL-1 is released in small 
quantities from the cell in response to a further stimulation, 
either by the same or additional agents. This release could 
be due to some loss in cell viability or transient disruptions 
in the plasma membrane.  Processing then occurs either at 
this latter step or immediately  thereafter via membrane or 
extracellular proteases. 
The key to this model is the very high specific activity of 
IL-1, which requires the release of very small quantities of 
mature protein. The model also implies that transcriptional 
activation by itself is not necessarily enough to allow expres- 
sion of secreted IL-1.  Clearly,  the availability of cell lines 
which constitutively express precursor IL-1 will allow us to 
test the nature of the steps which are required for release of 
IL- 1. In addition we can begin to ask what role the conserved 
precursor portion of IL-1 might play in this process, if any, 
especially  since  the existence  of further  secreted  proteins 
which  lack  conventional 'signal'  sequences  such  as  basic 
fibroblast growth factor (1) suggests that these mechanisms 
may not be specific  to IL-1. 
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